Dassault Systèmes

Dassault Systèmes SE (Euronext Paris: DSY.PA, ISIN FR0014003TT8; CAC 40 constituent) is a profitable, founder-anchored French enterprise-software company incorporated 9 June 1981 as a spin-off of Avions Marcel Dassault. HQ at 10 Rue Marcel Dassault, Vélizy-Villacoublay; regional campuses in Waltham, Massachusetts and Shanghai. ~25,000 employees across 184+ offices.

Groupe Industriel Marcel Dassault (GIMD) holds approximately 40–41% of capital and ~53–57% of voting rights through double-voting on registered shares; Charles Edelstenne holds ~6%. CEO Pascal Daloz (since 1 January 2024, succeeding Bernard Charlès) was appointed Chairman & CEO on 21 February 2026 after Bernard Charlès stepped down as Executive Chairman "for personal reasons, with immediate effect." CFO is Rouven Bergmann; EVP R&D is Florence Hu-Aubigny.

For pharma buyers, the relevant brands are BIOVIA (scientific innovation: ONE Lab, Pipeline Pilot, Discovery Studio, Materials Studio, COSMO-RS, QUMAS EDMS, Insight, Discoverant, Generative Therapeutics Design, BIOVIA Draw) and DELMIA (digital manufacturing: Apriso MOM/MES, Quintiq supply chain, Ortems APS, DELMIAWorks mid-market ERP+MES from the 2018 IQMS acquisition, 3DLean, Augmented Experience from the 2022 Diota acquisition). Pharma-relevant acquisitions: Accelrys (April 2014, ~$750M) became BIOVIA and pulled in QUMAS EDMS and Aegis Discoverant; Apriso (2013) became DELMIA Apriso; Medidata ($5.8B, closed October 2019) on the clinical-trial side; IQMS ($425M, 2018–2019) became DELMIAWorks.

ChemDraw is not a Dassault product — it belongs to Revvity Signals (CambridgeSoft -> PerkinElmer 2011 -> Revvity 2023). BIOVIA's own chemical-structure drawing tool is BIOVIA Draw.

Life Sciences is the company's second largest core industry after Transportation & Mobility, materially expanded by Medidata (clinical trials, $5.8B, Oct 2019) and Accelrys/BIOVIA (scientific informatics, April 2014). Vendor reports BIOVIA solutions are used by "25 of the top 25 pharmaceutical companies and 25 of the top 25 biotech companies."

Publicly disclosed pharma customer references: Pfizer (BIOVIA Pipeline Pilot and Biological & Chemical Registration); Bristol Myers Squibb (multi-year extension of Medidata Platform announced 7 April 2025); Sanofi, GSK, AstraZeneca, and Merck referenced collectively as "top 20 biopharma" customers; Aboca (BIOVIA ONE Lab paperless lab); Vertex Pharmaceuticals (long-time QUMAS EDMS customer per third-party analysis).

Compliance posture: BIOVIA ONE Lab and QUMAS EDMS are explicitly marketed for FDA 21 CFR Part 11 and EU Annex 11 with audit trails, electronic signatures, and GLP/GMP support. The 3DEXPERIENCE platform is positioned as "GxP-ready by design" with GAMP 5-aligned validation packages, an optional pre-production cloud staging environment, an Installation Verification Report supporting customer IQ, and BIOVIA Validation Kits that allow up to five validated SaaS releases per year. Vendor reports SOC 2 and ISO 27001 alignment for cloud operations on OUTSCALE (France SecNumCloud high-security certification).

FY2024: revenue €6.21B (+5% reported, software +6%); non-IFRS operating margin 31.9%; non-IFRS diluted EPS €1.28 (+9% cc); IFRS operating income €1.36B; cash flow from operations €1.66B; net cash position €1.46B at year-end. FY2025: revenue €6.24B (+4% cc); recurring revenue +6%; subscription +11%; 3DEXPERIENCE +10%; Cloud +8%. FY2026 guidance initiated at 3–5% revenue growth, a deceleration versus earlier years.

At Q3 (22 October 2025), DS cut FY2025 guidance from 6–8% to 4–6% revenue growth, while reaffirming EPS growth of 7–10%. Daloz characterised this as a risk-adjusted outlook reflecting Manufacturing softness and selective Life Sciences (Medidata) recovery.

Pharma-relevant acquisition history: Apriso 2013 (DELMIA Apriso MOM/MES); Quintiq 2014 (supply chain); Accelrys 2014 (~$750M, became BIOVIA including QUMAS EDMS and Aegis Discoverant); Centric Software majority 2018 (PLM); IQMS 2018–2019 ($425M, became DELMIAWorks); Medidata 2019 ($5.8B, clinical trials/RWD); NuoDB 2020 (cloud-native distributed SQL); Proxem 2020 (NLP); Diota 2022 (DELMIA Augmented Experience); Centric/Contentserv 2025 (€220M, PIM/PXM).

Dassault Systèmes operates 12+ commercial brands on a single underlying 3DEXPERIENCE platform (cloud and on-premise), sold either as integrated suites or as modular Roles. For pharma buyers the key brands are BIOVIA (scientific innovation) and DELMIA (digital manufacturing and operations); CATIA, ENOVIA, SIMULIA, SOLIDWORKS, and Medidata round out the broader portfolio.

The 3DEXPERIENCE Platform is the cloud-based collaborative layer connecting people, ideas, data, and solutions across the value chain from design to manufacturing to service. CATIA is 3D design and engineering software for product development, used in aerospace, automotive, and industrial equipment. SOLIDWORKS is 3D CAD software for mechanical design, used by millions of engineers and designers worldwide. ENOVIA is a product lifecycle management (PLM) and collaboration platform for managing product data and processes. DELMIA covers digital manufacturing and operations management, including production planning, simulation, and manufacturing execution systems (MES); DELMIA Apriso provides manufacturing operations management (MOM) for real-time shop floor control. SIMULIA provides simulation and analysis tools for testing product performance, durability, and manufacturability virtually. BIOVIA is the scientific innovation software for life sciences, materials science, and chemical R&D, including laboratory informatics and molecular modeling.

Cloud-based delivery through the 3DEXPERIENCE platform lets companies digitally design, test, and manufacture products before physical production. Integration across the portfolio lets organisations build digital twins connecting virtual design with real-world manufacturing operations.

Hyperscalers: vendor reports cloud deployments on AWS, Microsoft Azure, and DS's OUTSCALE sovereign cloud (highest French SecNumCloud certification). NVIDIA (3 Feb 2026 at 3DEXPERIENCE World): BIOVIA + BioNeMo "virtual twin factory" for therapeutic modalities, BIOVIA + ALCHEMI for materials, SIMULIA + CUDA-X, DELMIA + Omniverse Physical AI for "software-defined factories." Mistral AI (26 Nov 2025): Le Chat Enterprise and AI Studio on OUTSCALE, targeted at regulated industries.

Strategic alliance partners on 3DEXPERIENCE include Accenture, Capgemini, and IBM with formal joint go-to-market. Boutique DELMIA Apriso integrators include Andea (SOC 2 Type II audited Apriso & Ortems VAR), TriMech, TECHNIA, Keonys, D4M, and GoEngineer across DELMIA and BIOVIA portfolios. Pharma validation services (CSV / GAMP5) are typically delivered by partners or by DS's own services organisation. DS/BIOVIA participates in ISPE (Pharma 4.0) and Pharma IQ events.

Support and professional services are delivered both directly and through an authorized partner network.

Implementation services for DELMIA Apriso and other products are delivered through authorized implementation partners, who provide deployment, customization, configuration, validation assistance, and cloud migration services; the partner network includes specialized firms with industry expertise in manufacturing execution systems, PLM, and digital manufacturing. Partner firms offer training programs for end users, administrators, and technical staff, covering system configuration, best practices, and industry-specific use cases such as FDA compliance for life sciences.

Support is available through Dassault Systèmes and authorized partners, drawing on the company's presence across 184 offices in multiple regions (41% Europe, 32% Asia-Oceania, 27% Americas) to span multiple time zones and languages. Product documentation is maintained by Dassault Systèmes, with DELMIA Apriso 2025 Documentation available through the official support portal.

Dassault Systèmes states that successful DELMIA Apriso implementations depend on the implementation partner chosen: more than 50% of implementation responsibility typically falls on the customer and partner rather than the vendor.

Leadership: Pascal Daloz is Chairman & CEO (Chairman since 21 February 2026; CEO since 1 January 2024; previously Deputy CEO from 2018, with CFO/strategy roles since 2007). Bernard Charlès (43-year tenure, CEO 1995–2023, Executive Chairman 2024–Feb 2026) stepped down 21 February 2026 "for personal reasons, with immediate effect." Florence Hu-Aubigny is EVP R&D; Rouven Bergmann is CFO. BIOVIA leadership has historically run from San Diego (Scott Hiraoka, SVP BIOVIA per public profile data).

Analyst recognition: DELMIA Apriso has been included in the Gartner Magic Quadrant for MES (2022 and 2023 editions confirmed in public summaries). Gartner commentary notes Apriso's strength in complex discrete and batch/repetitive flow manufacturing, ongoing microservices migration, and integration depth via 3DEXPERIENCE. ISO/SOC: vendor reports compliance with ISO 27001 and SOC 2 controls for cloud delivery; OUTSCALE holds France's SecNumCloud high-security certification.

Thought leadership: 3DEXPERIENCE World (annual, Houston for 2025 and 2026 editions), 3DEXPERIENCE Forum (executive event, Boston March 2026, Capgemini Platinum sponsor), BIOVIA Live regional user events, DELMIA User Champion programme, and historically Science in the Age of Experience.

The company operates www.3ds.com as its primary corporate website, alongside product-specific sites and documentation portals.

Dassault Systèmes provides product documentation, case studies, and resources for customers and prospects; DELMIA Apriso 2025 Documentation is available through the official support portal.

An extensive network of authorized implementation partners, value-added resellers, and system integrators promotes and delivers Dassault Systèmes solutions including DELMIA Apriso.

The historical customer base includes major global manufacturers across aerospace (Lockheed Martin), automotive (General Motors, Volvo CE), consumer goods (L'Oréal, L'Occitane), tobacco (Philip Morris International, British American Tobacco), and industrial equipment (Hitachi, Cummins, Bombardier).